WebDisclosure WebDisclosure
Basculer en Français
10053 Companies
205214 Keywords
135462 Articles
108806 Press releases
Headlines Articles Press releases AL-S Pharma AG Remove
  1. Home
  2. Companies
  3. AL-S Pharma AG
WebDisclosure
Basculer en Français
Headlines Articles Press releases

News

  • BRIEF

    published on 03/19/2026 at 07:35, 3 hours 1 minute ago

    AL-S Pharma's AP-101 Shows Promise in ALS Treatment

    Clinical Trial ALS Treatment Phase 2 Data AP-101 SOD1 Targeting
  • BRIEF

    published on 03/19/2026 at 07:35, 3 hours 1 minute ago

    Le traitement AP-101 d'AL-S Pharma se révèle prometteur dans le traitement de la SLA.

    Essai Clinique Traitement De La SLA Données De La Phase 2 AP-101 Ciblage SOD1
  • PRESS RELEASE

    published on 03/19/2026 at 07:30, 3 hours 6 minutes ago

    Additional Phase 2 Data of AL-S Pharma’s Lead Program AP-101 Further Demonstrate Clinically Meaningful Disease Modification and Prolonged Survival in ALS

    AL-S Pharma AG presents additional Phase 2 data of lead program AP-101 at AD/PD International Conference showing disease modification in ALS patients. AP-101 targets misfolded SOD1 to inhibit disease progression
    ALS Phase 2 Data AP-101 AL-S Pharma AG SOD1
    Logo of AL-S Pharma AG
Accesswire
  • Published on 03/19/2026 at 07:30, 3 hours 6 minutes ago

    Tocvan Drone Magnetic Data Strengthens Gold-Silver Targets Across Gran Pilar; Identifies Broad Zones for Expansion Potential

  • Published on 03/19/2026 at 06:35, 4 hours 1 minute ago

    Golden Lake Announces Securityholder Approval of Arrangement with McEwen Inc.

  • Published on 03/19/2026 at 01:05, 9 hours 31 minutes ago

    Prospect Ridge Announces Closing of Flow-Through Share Private Placement

  • Published on 03/18/2026 at 23:45, 10 hours 51 minutes ago

    Orogen Royalties Announces Private Placement Update

  • Published on 03/18/2026 at 21:00, 13 hours 36 minutes ago

    PLDT's Smart Selects Amdocs to Transform Retail Operations with AI-Powered Store Genie

View all ACCESSWIRE
EQS Group
  • Published on 03/19/2026 at 10:14, 22 minutes ago

    Pentixapharm Holding AG will publish its financial report for the 2025 fiscal year on March 26, 2026

  • Published on 03/19/2026 at 10:05, 31 minutes ago

    Shipsy Launches AgentFleet, an AI Workforce for Logistics Operations

  • Published on 03/19/2026 at 10:05, 31 minutes ago

    Villeroy & Boch successfully holds its own in the 2025 financial year despite challenging market conditions

  • Published on 03/19/2026 at 10:00, 35 minutes ago

    Original-Research: Finexity AG (von GBC AG): BUY

  • Published on 03/19/2026 at 09:30, 1 hour 6 minutes ago

    DN Group AG: First International Impact Forum 2026 in Monaco focused on Circular & Blue Economy

View all EQS
Les Echos
  • Published on 03/19/2026 at 08:45, 1 hour 51 minutes ago

    Deezer et Sonos renouvellent et étendent leur partenariat stratégique

  • Published on 03/19/2026 at 08:45, 1 hour 51 minutes ago

    Deezer and Sonos renew and expand long-term collaboration

  • Published on 03/19/2026 at 07:00, 3 hours 36 minutes ago

    bioMérieux Receives IVDR CE‑Marking for Two BIOFIRE® SPOTFIRE® Panels to Strengthen Near‑Patient Respiratory and Sore Throat Diagnostics Across Europe

  • Published on 03/19/2026 at 07:00, 3 hours 36 minutes ago

    bioMérieux obtient le marquage CE IVDR pour deux tests BIOFIRE® SPOTFIRE® afin de renforcer en Europe le diagnostic des infections respiratoires et pharyngées au plus près du patient

  • Published on 03/19/2026 at 07:00, 3 hours 36 minutes ago

    Résultats annuels 2025 et nouvelle signature stratégique

View all LES ECHOS COMFI WIRE

With webdisclosure.com, you can follow all the latest financial news in real time from the best sources for companies listed on the Paris, Brussels, Amsterdam, Lisbon, Frankfurt and New York stock exchanges. You'll have access to summary articles written by us and press releases published by the companies themselves.

©Dissemination technology Webdisclosure.com - copyright 2026 SYMEX ECONOMICS all rights reserved

WebDisclosure

87, rue Ordener - 75018 Paris

Contact us

+33 1 42 23 83 61

Contact Authors Cookies policy Terms and conditions Privacy policy